MRNA · Moderna, Inc. · Webcasts, Transcripts & Audio
$223.37
-7.98 (-3.45%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$90.38B
Shares
404.62M
Volume · Nov 13
8.09M
Avg daily vol (3M)
21.79M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Moderna, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Moderna, Inc. (MRNA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-18
Moderna, Inc. (MRNA) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Capital Markets Day
Investor event
2026-11-12
Moderna, Inc. (MRNA) November 12, 2026 Capital Markets Day
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-06
Moderna, Inc. (MRNA) Q3 2026 Earnings Call Transcript
Revenue
$1.31B
▲ 29.2% YoY Diluted EPS
$0.38
Gross margin
75.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Moderna, Inc. (MRNA) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-31
Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript
Positive tone
COVID vaccination rate uncertainty
Financial discipline and cost reduction
Leadership appointments
Revenue
$145.00M
▲ 2.1% YoY Diluted EPS
$-1.97
Gross margin
35.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Moderna, Inc. (MRNA) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-01
Moderna, Inc. (MRNA) Q1 2026 Earnings Call Transcript
Confident tone
Intismeran oncology pipeline
Q1 financial performance and revenue growth
Pandemic flu mRNA-1018 with BARDA
Revenue
$389.00M
▲ 260.2% YoY Diluted EPS
$-3.40
Gross margin
-145.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-13
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
Balanced tone
Oncology pipeline (INT, mRNA-4259)
COVID franchise and Spikevax/MNEXT Spike
2026 financial outlook
Revenue
$678.00M*
▼ 29.8% YoY Gross margin
33.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Moderna, Inc. (MRNA) Q3 2025 Earnings Call Transcript
Balanced tone
Strategic manufacturing partnerships
Cost reduction and financial discipline
COVID vaccine commercial performance
Revenue
$1.02B
▼ 45.4% YoY Diluted EPS
$-0.51
▼ 1800% YoY Gross margin
79.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-01
Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript
Balanced tone
Flu and COVID combination pipeline
CMV vaccine program
FDA approvals for commercial products
Revenue
$142.00M
▼ 41.1% YoY Diluted EPS
$-2.13
Gross margin
16.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript
Balanced tone
Cost reduction and financial discipline
Pipeline and clinical programs
Regulatory and political risk
Revenue
$108.00M
▼ 35.3% YoY Diluted EPS
$-2.52
Gross margin
16.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-14
Moderna, Inc. (MRNA) Q4 2024 Earnings Call Transcript
Balanced tone
Norovirus clinical hold
mRESVIA (RSV) launch and expansion
Financial results and 2024 cost reductions
Revenue
$966.00M*
▼ 65.6% YoY Gross margin
23.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Moderna, Inc. (MRNA) Q3 2024 Earnings Call Transcript
Balanced tone
COVID vaccine market and share
Pipeline / oncology INT program
RSV (mRESVIA)
Revenue
$1.86B
▲ 1.7% YoY Diluted EPS
$0.03
Gross margin
72.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Moderna, Inc. (MRNA) Q2 2024 Earnings Call Transcript
Positive tone
COVID-19 franchise and competition
RSV launch (mRESVIA)
Flu and combo vaccines
Revenue
$241.00M
▼ 29.9% YoY Diluted EPS
$-3.33
Gross margin
52.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Moderna, Inc. (MRNA) Q1 2024 Earnings Call Transcript
Positive tone
Late-Stage Pipeline and Clinical Progress
Individualized Neoantigen Therapy (INT)
International RSV and EU Tender
Revenue
$167.00M
▼ 91% YoY Diluted EPS
$-3.07
▼ 1715.8% YoY Gross margin
42.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Moderna, Inc. (MRNA) Q4 2023 Earnings Call Transcript
Balanced tone
Individualized Neoantigen Therapy (INT) oncology program
CMV latent vaccine program
Rare disease programs (Propionic Acidemia, MMA)
Revenue
$2.81B*
▼ 44.7% YoY Gross margin
67.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Moderna, Inc. (MRNA) Q3 2023 Earnings Call Transcript
Revenue
$1.83B
▼ 45.6% YoY Diluted EPS
$-9.53
▼ 476.7% YoY Gross margin
-22.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Moderna, Inc. (MRNA) Q2 2023 Earnings Call Transcript
Revenue
$344.00M
▼ 92.8% YoY Diluted EPS
$-3.62
▼ 169.1% YoY Gross margin
-112.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Moderna, Inc. (MRNA) Q1 2023 Earnings Call Transcript
Revenue
$1.86B
▼ 69.3% YoY Diluted EPS
$0.19
▼ 97.8% YoY Gross margin
57.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Moderna, Inc. (MRNA) Q4 2022 Earnings Call Transcript
Revenue
$5.08B*
▼ 29.5% YoY Gross margin
62.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Date not confirmed
Moderna, Inc. (MRNA) Q3 2022 Earnings Call Transcript
Revenue
$3.36B
▼ 32.3% YoY Diluted EPS
$2.53
▼ 67.1% YoY Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Moderna, Inc. (MRNA) Q2 2022 Earnings Call Transcript
Revenue
$4.75B
▲ 9.1% YoY Diluted EPS
$5.24
▼ 18.9% YoY Gross margin
70.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Moderna, Inc. (MRNA) Q1 2022 Earnings Call Transcript
Revenue
$6.07B
▲ 213.2% YoY Diluted EPS
$8.58
▲ 202.1% YoY Gross margin
83.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Moderna, Inc. (MRNA) Q4 2021 Earnings Call Transcript
Revenue
$7.21B*
▲ 1162.9% YoY Gross margin
86.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Moderna, Inc. (MRNA) Q3 2021 Earnings Call Transcript
Revenue
$4.97B
▲ 3065% YoY Diluted EPS
$7.70
Gross margin
85.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Moderna, Inc. (MRNA) Q2 2021 Earnings Call Transcript
Revenue
$4.35B
▲ 6398.5% YoY Diluted EPS
$6.46
Gross margin
82.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Moderna, Inc. (MRNA) Q1 2021 Earnings Call Transcript
Revenue
$1.94B
▲ 24112.5% YoY Diluted EPS
$2.84
Gross margin
90.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Moderna, Inc. (MRNA) Q4 2020 Earnings Call Transcript
Revenue
$571.00M*
▲ 3962.6% YoY Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Moderna, Inc. (MRNA) Q3 2020 Earnings Call Transcript
Revenue
$157.00M
▲ 821% YoY Diluted EPS
$-0.59
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Moderna, Inc. (MRNA) Q2 2020 Earnings Call Transcript
Revenue
$67.00M
▲ 412.1% YoY Diluted EPS
$-0.31
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Moderna, Inc. (MRNA) Q1 2020 Earnings Call Transcript
Revenue
$8.00M
▼ 50.1% YoY Diluted EPS
$-0.35
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Moderna, Inc. (MRNA) Q4 2019 Earnings Call
Revenue
$14.05M
▼ 60.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 webcasts
Key facts
CIK
1682852
CUSIP
60770K107
13F (30d)
869 filings
784 filers
Visit website
Investor relations